8 Results for "

geographic atrophy

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "geographic atrophy" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P3252A
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD) .
loading...
    loading...
Cat. No.: HY-148457
CAS No.: 1613641-69-2
Synonyms: Izervay
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA .
loading...
    loading...
Cat. No.: HY-148370A
CAS No.: 2272983-11-4
Purity:  93.90%
Synonyms: IONIS-FB-LRx sodium; RG6299 sodium; ISIS 696844 sodium
Target:  

Complement System

Research Areas:  

Others

Sefaxersen sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research .
loading...
    loading...
Cat. No.: HY-148370
CAS No.: 2272975-74-1
Synonyms: IONIS-FB-LRx; RG6299; ISIS 696844
Target:  

Complement System

Research Areas:  

Others

Sefaxersen (IONIS-FB-LRx) is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen effectively reduces circulating levels of CFB. Sefaxersen can be used for geographic atrophy (GA) research .
loading...
    loading...
Cat. No.: HY-N0679S
CAS No.: 118139-36-9
Synonyms: ALK-001; Retinol acetate-d3; Vitamin A acetate-d3
Retinyl acetate-d3 (ALK-001) is a deuterated Vitamin A. Retinyl acetate-d3 can be used for research of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) .
loading...
    loading...
Cat. No.: HY-106429
CAS No.: 627085-11-4
Research Areas:  

Others

OT-551 (free base) is a lipophilic, disubstituted hydroxylamine with antioxidant properties. OT-551 can be used as an eye drop and can be converted by intraocular esterases to its active metabolite, Tempol-H (TP-H). OT-551 can be utilized in geographic atrophy and macular degeneration research .
loading...
    loading...
Cat. No.: HY-P991534

Target:  

Amyloid-β

Research Areas:  

Neurological Disease

PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
loading...
    loading...
Cat. No.: HY-P992142
CAS No.: 3050549-24-8
Synonyms: ANX-007

Target:  

Complement System

Vonaprument (ANX-007) is an intravitreally injected C1q antibody fragment (with a molecular weight of approximately 48 kDa) and a human monoclonal antibody. Vonaprument inhibits the activation of the classical complement cascade by specifically recognizing the globular head of C1q and blocking substrate binding. After intravitreal injection, Vonaprument distributes to the retina, choroid and optic nerve, and achieves complete C1q target binding in the aqueous humor and retinal tissues. Vonaprument can be used in research related to neurodegenerative eye diseases such as age-related macular degeneration and glaucoma .
loading...
    loading...